Rita Nanda

17.0k citations

205 papers · 6.3k indexed · 5 hit papers · h-index 34

Impact in

Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis

Papers in ⓘ

Oncology 148
- HER2/EGFR in Cancer Research 49
- Cancer Immunotherapy and Biomarkers 47
- Cancer Treatment and Pharmacology 28
- PARP inhibition in cancer therapy 20
Cancer Research 68
- Breast Cancer Treatment Studies 43
- Cancer Genomics and Diagnostics 35

Co-authors: Olufunmilayo I. Olopade (34 shared papers)Charles M. Perou (8 shared papers)Chad Livasy (1 shared paper)Gamze Karaca (1 shared paper)Dominic T. Moore (1 shared paper)Maria Tretiakova (2 shared papers)Peter Schmid (12 shared papers)Dezheng Huo (24 shared papers)
Journals: Journal of Clinical Oncology (74 papers)Cancer Research (44 papers)Annals of Oncology (11 papers)Breast Cancer Research and Treatment (11 papers)Clinical Cancer Research (7 papers)
Partner nations: United States United Kingdom Spain

In The Last Decade

Rita Nanda

189 papers receiving 6.2k citations

Hit Papers

5 papers align trajectories log scale

Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database 2023 · 86 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 JAMA Oncology
2018 Journal of Clinical Oncology
2018 JAMA Oncology
2018 Annals of Oncology
2005 Modern Pathology

Peers

Countries citing papers authored by Rita Nanda

Since Specialization

Citations

This map shows the geographic impact of Rita Nanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rita Nanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rita Nanda more than expected).

Fields of papers citing papers by Rita Nanda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rita Nanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rita Nanda. The network helps show where Rita Nanda may publish in the future.

Co-authors

The 25 scholars most cited alongside Rita Nanda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rita Nanda Line = papers co-authored together Rita Nanda links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 205 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma Modern Pathology ·Chad Livasy, Gamze Karaca, Rita Nanda, Maria Tretiakova, Olufunmilayo I. Olopade, Dominic T. Moore, Charles M. Perou Hit paper breakdown →	2005	839
2	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer JAMA Oncology ·Leisha A. Emens, Cristina Cruz, Joseph P. Eder, Fadi Braiteh, Cathie T. Chung, Sara M. Tolaney, Irene Kuter, Rita Nanda, Philippe A. Cassier, Jean‐Pierre Delord, Michael S. Gordon, Ehab A. ElGabry, Ching-Wei Chang, Indrani Sarkar, William Grossman, Carol O’Hear, Marcella Fassò, Luciana Molinero, Peter Schmid Hit paper breakdown →	2018	567
3	Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Annals of Oncology ·Sylvia Adams, Sherene Loi, Deborah Toppmeyer, David W. Cescon, Michelino De Laurentiis, Rita Nanda, Eric P. Winer, Hirofumi Mukai, Kenji Tamura, Anne Armstrong, M.C. Liu, Hiroji Iwata, L Ryvo, Pauline Wimberger, Hope S. Rugo, Antoinette R. Tan, Lin Jia, Yu Ding, Vassiliki Karantza, Peter Schmid Hit paper breakdown →	2018	460
4	Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer Journal of Clinical Oncology ·Tiffany A. Traina, Kathy D. Miller, Denise A. Yardley, Janice F. Eakle, Lee S. Schwartzberg, Joyce O’Shaughnessy, William J. Gradishar, Peter Schmid, Eric P. Winer, Catherine M. Kelly, Rita Nanda, Ayca Gucalp, Ahmad Awada, Laura García‐Estévez, Maureen Trudeau, Joyce Steinberg, Hirdesh Uppal, Iulia Cristina Tudor, Amy Peterson, Javier Cortés Hit paper breakdown →	2018	348
5	Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer Journal of Clinical Oncology ·Dezheng Huo, Francis Ikpatt, Andrey Khramtsov, Jean-Marie Dangou, Rita Nanda, James J. Dignam, Bifeng Zhang, Tatyana A. Grushko, Chunling Zhang, Olayiwola Oluwasola, David Malaka, Sani Malami, Abayomi Odetunde, Adewumi O. Adeoye, Festus Iyare, Adeyinka G. Falusi, Charles M. Perou, Olufunmilayo I. Olopade	2009	287
6	Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women JAMA ·Rita Nanda, L. Philip Schumm, Shelly Cummings, James D. Fackenthal, Lise Sveen, Foluso O. Ademuyiwa, Melody Cobleigh, Laura J. Esserman, Noralane M. Lindor, Susan L. Neuhausen, Olufunmilayo I. Olopade	2005	192
7	Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006 Journal of Clinical Oncology ·Mothaffar F. Rimawi, Ingrid A. Mayer, Andres Forero, Rita Nanda, Matthew P. Goetz, Angel Rodriguez, Anne C. Pavlick, Tao Wang, Susan G. Hilsenbeck, Carolina Gutiérrez, Rachel Schiff, C. Kent Osborne, Jenny C. Chang	2013	187
8	The role of tumor-associated macrophages in breast cancer progression International Journal of Oncology ·Elias Obeid, Rita Nanda, Yang‐Xin Fu, Olufunmilayo I. Olopade	2013	169
9	Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. Journal of Clinical Oncology ·Rita Nanda, Minetta C. Liu, Christina Yau, Smita Asare, Nola Hylton, Laura van’t Veer, Jane Perlmutter, Anne M. Wallace, A. Jo Chien, Andres Forero‐Torres, Erin D. Ellis, Heather Han, Amy S. Clark, Kathy S. Albain, Judy C. Boughey, Anthony Elias, Donald A. Berry, Douglas Yee, Angela DeMichele, Laura Esserman	2017	158
10	Advances in Breast Cancer: Pathways to Personalized Medicine Clinical Cancer Research ·Olufunmilayo I. Olopade, Tatyana A. Grushko, Rita Nanda, Dezheng Huo	2008	158
11	Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer Cancer ·Jennifer F. De Los Santos, Alan Cantor, Keith D. Amos, Andres Forero, Mehra Golshan, Janet K. Horton, Clifford A. Hudis, Nola M. Hylton, Kandace P. McGuire, Funda Meric‐Bernstam, Ingrid M. Meszoely, Rita Nanda, E. Shelley Hwang	2013	152
12	The impact of site-specific digital histology signatures on deep learning model accuracy and bias Nature Communications ·Frederick M. Howard, James M. Dolezal, Sara Kochanny, Jefree J. Schulte, Heather Chen, Lara R. Heij, Dezheng Huo, Rita Nanda, Olufunmilayo I. Olopade, Jakob Nikolas Kather, Nicole A. Cipriani, Robert L. Grossman, Alexander T. Pearson	2021	149
13	BRCA1 Promoter Methylation in Sporadic Breast Cancer Is Associated with Reduced BRCA1 Copy Number and Chromosome 17 Aneusomy Cancer Research ·Minjie Wei, Tatyana A. Grushko, James J. Dignam, Fitsum Hagos, Rita Nanda, Lise Sveen, Jinhua Xu, James D. Fackenthal, Maria Tretiakova, Soma Das, Olufunmilayo I. Olopade	2005	142
14	If we build it they will come: targeting the immune response to breast cancer npj Breast Cancer ·Margaret E. Gatti‐Mays, Justin M. Balko, Sofia R. Gameiro, Harry D. Bear, Sangeetha Prabhakaran, Jami Fukui, Mary L. Disis, Rita Nanda, James L. Gulley, Kevin Kalinsky, Houssein Abdul Sater, Joseph A. Sparano, David W. Cescon, David B. Page, Heather L. McArthur, Sylvia Adams, Elizabeth A. Mittendorf	2019	140
15	Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 Annals of Oncology ·Sherene Loi, Sylvia Adams, Peter Schmid, Javier Cortés, David W. Cescon, Eric P. Winer, Deborah Toppmeyer, Hope S. Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji Iwata, Ahmad Awada, Antoinette R. Tan, A. Wang, Gursel Aktan, Vassiliki Karantza, Roberto Salgado	2017	135
16	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer Clinical Cancer Research ·Brian D. Lehmann, Vandana G. Abramson, Melinda E. Sanders, Erica L. Mayer, Tufia C. Haddad, Rita Nanda, Catherine Van Poznak, Anna Maria Storniolo, Julie R. Nangia, Paula I. González-Ericsson, Violeta Sánchez, Kimberly N. Johnson, Richard G. Abramson, Sheau‐Chiann Chen, Yu Shyr, Carlos L. Arteaga, Antonio C. Wolff, Jennifer A. Pietenpol	2019	113
17	Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). Journal of Clinical Oncology ·Tiffany A. Traina, Kathy D. Miller, Denise A. Yardley, Joyce O’Shaughnessy, Javier Cortés, Ahmad Awada, Catherine M. Kelly, Maureen Trudeau, Peter Schmid, Luca Gianni, Laura García‐Estévez, Rita Nanda, Foluso O. Ademuyiwa, Stephen Y. Chan, Joyce Steinberg, Martha Blaney, Iulia Cristina Tudor, Hirdesh Uppal, Amy Peterson, Clifford A. Hudis	2015	109
18	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. Journal of Clinical Oncology ·Sylvia Adams, Peter Schmid, Hope S. Rugo, Eric P. Winer, Delphine Loirat, Ahmad Awada, David W. Cescon, Hiroji Iwata, Mario Campone, Rita Nanda, Rina Hui, Giuseppe Curigliano, Deborah Toppmeyer, Joyce O’Shaughnessy, Sherene Loi, Shani Paluch–Shimon, Deborah Card, Jing Zhao, Vassiliki Karantza, Javier Cortés	2017	90
19	Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer Cancer Research ·Rita Nanda, Laura Q.M. Chow, E. Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Marisa Dolled‐Filhart, Kenneth Emancipator, Edward J. Gonzalez, Jennifer Houp, Kumudu Pathiraja, Vassiliki Karantza, Robert Iannone, Christine K. Gause, Johnathan D Cheng, Laurence Buisseret	2015	87
20	Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database JAMA Oncology ·Daniel S. Peiffer, Fangyuan Zhao, Nan Chen, Olwen Hahn, Rita Nanda, Olufunmilayo I. Olopade, Dezheng Huo, Frederick M. Howard Hit paper breakdown →	2023	86

About Rita Nanda

Rita Nanda is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 205 papers that have together received 6.3k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (62 papers), HER2/EGFR in Cancer Research (49 papers), Cancer Immunotherapy and Biomarkers (47 papers), Breast Cancer Treatment Studies (43 papers), Cancer Genomics and Diagnostics (35 papers), Cancer Treatment and Pharmacology (28 papers), PARP inhibition in cancer therapy (20 papers) and BRCA gene mutations in cancer (15 papers). The work is most often cited by research in Cancer Research (2.5k citations), Oncology (4.3k citations), Immunology (1.1k citations), Pulmonary and Respiratory Medicine (1.4k citations) and Radiology, Nuclear Medicine and Imaging (701 citations). Rita Nanda has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Olufunmilayo I. Olopade, Charles M. Perou, Chad Livasy, Gamze Karaca, Dominic T. Moore, Maria Tretiakova, Peter Schmid, Dezheng Huo, Tatyana A. Grushko and Eric P. Winer. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Breast Cancer Research and Treatment and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact